Abstract B35: Liaison between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in fusion-negative rhabdomyosarcoma

Abstract B35: Liaison between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in fusion-negative rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is a pediatric malignancy of the muscle, and patients with high-risk fusion-negative RMS (FN-RMS), the major subtype of this disease, are associated with RAS pathway activating mutations and have a poor survival rate of

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2020-07, Vol.80 (14_Supplement), p.B35-B35
Hauptverfasser: Pomella, Silvia, Sreenivas, Prethish, Gryder, Berkley E., Wang, Long, Cassandri, Matteo, Baxi, Kunal, Hensch, Nicole R., Carcarino, Elena, Song, Young, Yohe, Marielle, Amadio, Bruno, Caruana, Ignazio, De Stefanis, Cristiano, De Vito, Rita, Locatelli, Franco, Chen, Yidong, Chen, Eleanor Y., Houghton, Peter, Khan, Javed, Rota, Rossella, Ignatius, Myron S.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Rhabdomyosarcoma (RMS) is a pediatric malignancy of the muscle, and patients with high-risk fusion-negative RMS (FN-RMS), the major subtype of this disease, are associated with RAS pathway activating mutations and have a poor survival rate of
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.PEDCA19-B35